Etop Ibcsg Partners Foundation

This phase 3 trial tests whether the immunotherapy drug cemiplimab can prevent lung cancer from returning after surgery in patients with stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 levels of 1% or higher. About 390 participants will either receive cem…

This study tests a drug called tarlatamab in people with advanced small cell lung cancer that has worsened after one prior treatment. About 48 participants will receive the drug by IV to see if it helps them live longer. The goal is to find a new option for patients who have limi…

This trial tests whether adding the drug niraparib to standard maintenance therapy can help people with a specific type of advanced small cell lung cancer (SLFN11-positive) stay cancer-free longer. About 44 participants will receive niraparib pills plus an anti-PD-L1 antibody aft…

This study is for people with a certain type of lung cancer (stage IIB-IIIB) that can be removed with surgery. Participants first get chemotherapy plus the immunotherapy drug durvalumab before surgery. After surgery, those whose cancer did not fully disappear are randomly assigne…

This study looks at whether adding a precise form of radiation (stereotactic radiosurgery) to standard drug therapy can better control brain metastases in people with melanoma or non-small cell lung cancer. About 180 participants with newly diagnosed, untreated brain metastases w…